Edison Investment Research - Worldwide Healthcare Trust (WWH) Worldwide Healthcare Trust - Sticking to the successful long-term strategy

Report

Edison Investment Research

Pedro Fonseca

Worldwide Healthcare Trust - Sticking to the successful long-term strategy

Worldwide Healthcare Trust’s (WWH’s) two co-managers, Sven Borho and Trevor Polischuk at specialist investor OrbiMed, remain positive on the prospects for the global healthcare industry. This view is based on favourable company fundamentals, increased clarity on US drug pricing and an upturn in merger and acquisition (M&A) activity, as pharma companies are using their strong balance sheets to bolster their product pipelines. The trust’s portfolio remains skewed to emerging (smaller-cap) biotech and emerging market stocks rather than large-cap pharma companies. While this strategy has been detrimental to WWH’s relative performance in recent quarters, this active approach has been successful over the longer term.

11/01/2023 1 EN

Underlying

Worldwide Healthcare Trust

Worldwide Healthcare Trust is an investment trust. Co. invest in the global healthcare sector particularly in pharmaceutical and biotechnology companies and related securities in the healthcare sector. In addition, Co. invests in medical device technologies, life science tools and healthcare services. A maximum of 20% of the portfolio, at the time of acquisition, may be invested in companies in each of the following sectors: healthcare equipment and supplies; healthcare technology; and healthcare providers and services. Co.'s investment portfolio at Mar 31 2017, principally comprised listed equity investments, OTC swaps and unquoted debt investments and totalled £1,192,881,000.

See profile

GB0003385308 London Stock Exchange United Kingdom

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Pedro Fonseca

Other Reports on these Companies

SmartInsider

Worldwide Healthcare Trust: 1 director

A director at Worldwide Healthcare Trust bought 7,250 shares at 345p and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names ...

Free Trial

October 2, 2024 October 2, 2024 1 EN

EQS Group AG

Edison issues review on Worldwide Healthcare Trust (WWH): Scope for the trust to get back on track in 2024

Edison Investment Research Limited Edison issues review on Worldwide Healthcare Trust (WWH): Scope for the trust to get back on track in 2024 08-Jan-2024 / 12:18 GMT/BST The issuer is solely responsible for the content of this announcement. London, UK, 8 January 2024 Edison issues review on Worldwide Healthcare Trust (WWH): Scope for the trust to get back on track in 2024 Worldwide Healthcare Trust’s (WWH’s) co-managers, Sven Borho and Trevor Polischuk, at global healthcare specialist OrbiMed, are disappointed with WWH’s performance as, in recent years, the trust has face...

January 8, 2024 January 8, 2024 1 EN

Edison Investment Research

Worldwide Healthcare Trust - Scope for the trust to get back on track in 2024

Worldwide Healthcare Trust’s (WWH’s) co-managers, Sven Borho and Trevor Polischuk, at global healthcare specialist OrbiMed, are disappointed with WWH’s performance as, in recent years, the trust has faced both top-down and bottom-up headwinds. The managers remain confident that investors will return to focusing on positive healthcare industry fundamentals, which include high levels of innovation, accompanied by an elevated number of new product approvals and robust M&A activity ahead of an upcoming patent cliff. Borho and Polischuk continue to favour the prospects for emerging (smaller-cap) bi...

January 8, 2024 January 8, 2024 1 EN

Foxtons Group - Deals' benefits matched by tax rise

Foxtons Group’s recent acquisition of estate agents in two London commuter towns highlights the outer-London potential for low-risk, value-added expansion. Furthermore, it adds to the developing success of the company’s strategic vision and implies that medium-term targets are now coming into focus. We have updated our forecasts for the deals, but additional profit from the acquisitions is broadly matched by the increase in employer’s National Insurance costs, hence we retain our valuation of 134p/share and believe that falling interest rates and property market stability are contributing to a...

12h / 36m 12h / 36m 1 EN

Pedro Fonseca

Pedro Fonseca

Partners Group Private Equity - Seeing good demand for several of its assets

Partners Group Private Equity’s (PGPE’s) recent portfolio realisation efforts (supported by the gradual pick-up in M&A activity and an opening IPO window) included, most notably, the sale of SRS Distribution earlier this year (see our September 2024 note for details) and more recently Techem (3.8% of end-Q324 NAV, sold to a trade buyer in October 2024), as well as the successful IPO pricing of Galderma in March and KinderCare in October. The positive valuation effects from these activities (21% weighted average uplift to latest published NAV) were coupled with a 5.1pp contribution to portfolio...

13h / 57m 13h / 57m 1 EN

Sean Conroy

Sean Conroy

Cereno Scientific - A productive period with plenty more to come

Cereno Scientific has released its Q324 results, marking a productive and strategically significant period. Following the positive top-line data from the Phase IIa safety study of CS1 in pulmonary arterial hypertension (PAH), Cereno decided to concentrate its development programmes on rare diseases. Key developments included the selection of idiopathic pulmonary fibrosis (IPF) as the target indication for second asset, CS014, and the positioning of its preclinical asset, CS585, towards rare disease indications. In November 2024, Cereno announced a SEK250m capital raise, extending its cash runw...

16h / 4m 16h / 4m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Worldwide Healthcare Trust - Sticking to the successful long-term strategy

Worldwide Healthcare Trust: 1 director

Edison issues review on Worldwide Healthcare Trust (WWH): Scope for the trust to get back on track in 2024

Worldwide Healthcare Trust - Scope for the trust to get back on track in 2024

Foxtons Group - Deals' benefits matched by tax rise

Partners Group Private Equity - Seeing good demand for several of its assets

Cereno Scientific - A productive period with plenty more to come

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe